Helen M. Thackray's Net Worth
$2.62 Million
Who is Helen M. Thackray?
Helen M. Thackray has an estimated net worth of $2.62 Million. This is based on reported shares across multiple companies, which include ImmunoGen, Inc., BIOCRYST PHARMACEUTICALS INC, and GLYCOMIMETICS INC.
SEC CIK
Helen M. Thackray's CIK is 0001589725
Past Insider Trading and Trends
2021 was Helen M. Thackray's most active year for acquiring shares with 8 total transactions. Helen M. Thackray's most active month to acquire stocks was the month of December. 2024 was Helen M. Thackray's most active year for disposing of shares, totalling 7 transactions. Helen M. Thackray's most active month to dispose stocks was the month of January. 2021 saw Helen M. Thackray paying a total of $262,680.00 for 926,500 shares, this is the most they've acquired in one year. In 2022 Helen M. Thackray cashed out on 10,725 shares for a total of $157,151.25, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ImmunoGen, Inc. (IMGN) No price found
InvestorHelen M. Thackray used to own units in Common Stock but no longer holds any shares there. From 2021 to 2024 Helen M. Thackray acquired a total of 3,074 shares in ImmunoGen, Inc. at a cost of $29,953.35, Helen also disposed a total of 3,074 shares of ImmunoGen, Inc..
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -3.07K |
—
|
—
|
0
|
Feb 12
| |||
Form 4
| +8.93% | 252 |
$29.65 | $7,471.80 | 3.07K |
Dec 29
| |||
Form 4
| +20.09% | 472 |
$15.87 | $7,490.64 | 2.82K |
Sep 29
| |||
Form 4
| +20.33% | 397 |
$18.87 | $7,491.39 | 2.35K |
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
∞
| 1.95K |
$3.84 | $7,499.52 | 1.95K |
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
BIOCRYST PHARMACEUTICALS INC (BCRX) Snapshot price: $8
Chief R&D OfficerHelen M. Thackray owns 272,139 units of Common Stock which is worth $2,177,112.00. From 2019 to 2024 Helen M. Thackray acquired a total of 306,000 shares in BIOCRYST PHARMACEUTICALS INC at a cost of $175,800.00, Helen also disposed a total of 33,861 shares of BIOCRYST PHARMACEUTICALS INC equalling to $306,656.58.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +12.39% | 30K |
$5.86 | $175,800.00 | 272.14K |
May 14
| |||
Form 4
| -3.01% | -7.53K |
$5.08 | -$38,227.00 | 242.14K |
Mar 31
| |||
Form 4
| -2.19% | -5.58K |
$6.05 | -$33,759.00 | 249.66K |
Dec 19
| |||
Form 4
| +23.14% | 47.97K |
$6.43 | -$19,489.33 | 255.24K |
Dec 14
| |||
Form 4
| -3.27% | -7.00K |
$8.29 | -$58,030.00 | 207.28K |
Apr 3
| |||
Form 4
| +60.78% | 81K |
—
|
—
| 214.28K |
Dec 19
| |||
Form 4
| -2.29% | -3.13K |
$10.89 | -$34,031.25 | 133.28K |
Scheduled
|
Dec 15
| ||
Form 4
| -5.28% | -7.60K |
$16.20 | -$123,120.00 | 136.4K |
Scheduled
|
Apr 1
| ||
Form 4
| +44.00% | 44K |
—
|
—
| 144K |
Dec 14
| |||
Form 4
|
∞
| 100K |
—
|
—
| 100K |
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GLYCOMIMETICS INC (GLYC) Snapshot price: $0.1596
SVP Clinical Development, CMOHelen M. Thackray owns 183,115 units of Common Stock which is worth $29,225.15. In the year 2014 Helen M. Thackray filed a total of 16 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +23.21% | 34.5K |
—
|
—
| 183.12K |
Jan 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 10
| |||
Form 4
| -1.33% | -2.00K |
$15.01 | -$30,020.00 | 148.62K |
Scheduled
|
Dec 8
| ||
Form 4
| -1.31% | -2.00K |
$13.00 | -$26,000.00 | 150.62K |
Scheduled
|
Sep 18
| ||
Form 4
| -1.29% | -2.00K |
$15.57 | -$31,140.00 | 152.62K |
Scheduled
|
May 25
| ||
Form 4
| -1.28% | -2.00K |
$12.14 | -$24,280.00 | 154.62K |
Scheduled
|
May 19
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
| -2.49% | -4.00K |
$7.00 | -$28,001.00 | 156.62K |
Scheduled
|
Oct 3
| ||
Form 4
| -1.23% | -2.00K |
$8.00 | -$16,000.00 | 160.62K |
Scheduled
|
Jul 20
| ||
Form 4
| -11.92% | -22.00K |
$7.00 | -$153,953.84 | 162.62K |
Scheduled
|
Jul 1 - Jul 6
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||